153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients

M. Berger, G. Grignani, A. Giostra, S. Ferrari, V. Ferraresi, A. Tamburini, G. Cefalo, F. Carnevale-schianca, E. Vassallo, P. Picci, M. Pagano, M. Aglietta, R. E. Pellerito, F. Fagioli

Research output: Contribution to journalArticle

Abstract

Background: Bone metastatic patients with osteosarcoma have a very poor prognosis. Targeted radiation therapy has been pursued as a valid alternative. The primary end point of this study was progression-free survival (PFS) at 4 months. Patients and methods: Twenty-two osteosarcoma patients were treated with Samarium-153 ethylenediaminetetramethylene phosphonic acid (. 153Sm-EDTMP) at various dosages. Administered activities ranged from 150 (3 mCi/kg) to 1140 MBq/kg (30 mCi/kg). Autologous hematopoietic stem cell infusion was carried out on day 14 after the . 153Sm-EDTMP infusion. Results: The median PFS was 61 days (18-436 days) and the median overall survival (OS) was 189 days (31-1175 days). PFS and OS for the entire patient population were 32% [95% confidence interval (CI) 16-50] and 76% (95% CI 52-89) at 4 months, respectively. No statistical differences emerged according to . 153Sm-EDTMP administered or 24-h retained activity. One-month pain palliation was only observed in a minority of subjects and in none at 4 months. Conclusions: Based on our series, the PFS is dramatically short even when higher activity of . 153Sm-EDTMP is administered. This would mean that, even at high level, . 153Sm-EDTMP is itself ineffective against relapsed osteosarcoma or the residual activity is too low to be active on these particular subsets of patients.

Original languageEnglish
Article numbermdr542
Pages (from-to)1899-1905
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number7
DOIs
Publication statusPublished - Jul 2012

Keywords

  • 153samarium-EDTMP administration
  • Hematopoietic stem cell rescue
  • Metastatic osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of '<sup>153</sup>Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients'. Together they form a unique fingerprint.

  • Cite this

    Berger, M., Grignani, G., Giostra, A., Ferrari, S., Ferraresi, V., Tamburini, A., Cefalo, G., Carnevale-schianca, F., Vassallo, E., Picci, P., Pagano, M., Aglietta, M., Pellerito, R. E., & Fagioli, F. (2012). 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Annals of Oncology, 23(7), 1899-1905. [mdr542]. https://doi.org/10.1093/annonc/mdr542